Co-Diagnostics: Hold Thesis Remains Well Intact

Sep. 07, 2022 10:46 AM ETCo-Diagnostics, Inc. (CODX)ABT7 Comments
Zach Bristow profile picture
Zach Bristow


  • We reiterate the hold thesis on Co-Diagnostics following Q2 FY22 earnings.
  • Covid-19 turnover continues to diminish for CODX whilst surging for rival test providers.
  • Inventory levels for the company spiked year over year as the Omicron-led demand in testing faded.
  • We've valued CODX at $3.24 suggesting shares are adequately priced by the market consensus.

Papid molecular assay, pcr analysis for express testing of novel novel 2019-nCoV coronavirus infection, viral pneumonia outbreak from China Multichannel pipette tips filled with reaction mixture.

anyaivanova/iStock via Getty Images

From the Portfolio Manager's Desk

Having witnessed the rapid cooling of Omicron-led demand in Covid-19 diagnostics, the Sars-CoV-2 assay market is looking increasingly unattractive. Here revisit Co-Diagnostics, Inc. (NASDAQ:CODX) a name that we are extremely


Data: HB Insights, CODX SEC Filings

This article was written by

Zach Bristow profile picture
Buy side equity portfolio strategist serving mandates throughout EU/US/APAC. Helping you position your portfolios for the future is my top priority. Shoot me a message to discuss trade ides or talk portfolio construction. Disclaimer:The opinions expressed in all articles do not constitute as investment advice. Please remember to conduct your own due diligence.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (7)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.